Lilly Scores New Treatment Option For Verzenios In England
Health technology assessment body NICE says that Verzenios when used with fulvestrant can be used to treat advanced breast cancer via the Cancer Drugs Fund, giving Eli Lilly the edge in this space for now over rival CDK4/6 manufacturers, Pfizer and Novartis.
You may also be interested in...
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
The SMC has given the all clear to funding for Lilly’s Verzenios for breast cancer, Richter’s Reagila for schizophrenia, and MSD’s Keytruda for melanoma. However, it rejected Alliance’s Xonvea for sickness in pregnancy because the evidence on benefits and cost effectiveness did not stack up.